Zymeworks Inc. (ZYME)

Market Cap	1.69B +76.8%
Revenue (ttm)	105.97M +38.9%
Net Income	-81.13M
EPS	-1.08
Shares Out	73.75M
PE Ratio	n/a
Forward PE	18.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	787,220
Open	23.42
Previous Close	23.23
Day's Range	22.43 - 23.89
52-Week Range	9.03 - 28.49
Beta	1.28
Analysts	Strong Buy
Price Target	38.90 (+70.02%)
Earnings Date	Mar 2, 2026

About ZYME

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead pr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 28, 2017
• Employees: 264
• Stock Exchange: NASDAQ
• Ticker Symbol: ZYME
• Website: https://www.zymeworks.com

Financial Performance

In 2025, Zymeworks's revenue was $105.97 million, an increase of 38.87% compared to the previous year's $76.30 million. Losses were -$81.13 million, -33.88% less than in 2024.

Analyst Summary

According to 11 analysts, the average rating for ZYME stock is "Strong Buy." The 12-month stock price target is $38.9, which is an increase of 70.02% from the latest price.

Price Target

$38.9

(70.02% upside)

Analyst Consensus: Strong Buy